Method for predicting the clinical response to chemotherapy in a subject with cancer

An object, cancer technology, applied in the field of diagnostics, capable of solving problems with negative effects, toxic quality of life, frequent occurrence, etc.

Inactive Publication Date: 2014-03-26
TRASLATIONAL CANCER DRUGS PHARMA SL
View PDF7 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although platinum-based combinations with newer agents have been widely accepted as first-line treatment for advanced NSCLC, the frequent occurrence of platinum resistance is currently a major obstacle in the treatment of these patients
In addition, there are many patients who receive chemotherapy without benefit, often experiencing unnecessary toxicity and negatively affecting their quality of life

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for predicting the clinical response to chemotherapy in a subject with cancer
  • Method for predicting the clinical response to chemotherapy in a subject with cancer
  • Method for predicting the clinical response to chemotherapy in a subject with cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0242] I. Materials and methods

[0243] patient

[0244] Patients were collected retrospectively between 2001 and 2008 at La Paz Hospital in Madrid (Spain). Inclusion criteria for the pilot study were patients with stage III to IV primary NSCLC who were 18 years or older and had received platinum-based chemotherapy as their initial treatment modality. Exclusion criteria were patients previously treated with chemotherapy or radiotherapy and patients for whom response could not be assessed. Only those specimens in paraffin-embedded tissue containing at least 80% of the pathological analysis of the tumor were included in the study. In conclusion, paraffin-embedded tumor lung tissue samples from 30 patients meeting the above criteria were retrospectively investigated.

[0245] Systemic chemotherapy with cisdiammine dichloroplatinum (CDDP) was used in all patients. Taking into account the chemotherapy regimen used, (paclitaxel) followed by cisplatin-gemcitabine-vinorelbine (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the use of choline kinase alpha as predictive marker for the determination of the response to a chemotherapeutic treatment in a subject suffering from cancer, particularly for predicting the clinical response of a subject suffering from non-small cell lung cancer to a platinum-based chemotherapeutic treatment. The invention relates to methods for designing a personalised therapy for subjects suffering from cancer, particularly from non- small cell lung cancer, based on the expression levels of choline kinase alpha as well as to methods for the treatment of non-small cell lung cancer using a platinum-based chemotherapeutic treatment based in a subject wherein the subject is selected based on the expression levels of choline kinase alpha.

Description

technical field [0001] The present invention relates to the field of diagnostics, and more particularly to a method for predicting the clinical response of a subject with cancer to chemotherapy treatment (chemotherapeutic treatment) based on the expression level of the ChoKα gene in a sample from the subject, especially for A method of predicting clinical response to platinum-based chemotherapeutic treatment in subjects with non-small cell lung cancer. The invention also relates to methods for designing individual therapies for subjects suffering from said diseases, and to methods for selecting patients who will respond to a given treatment. Background technique [0002] Conventional cancer control with chemotherapy (whether definitive or adjuvant) has improved absolute patient survival when compared to non-chemotherapy controls. However, not all available chemotherapeutic treatments are suitable for all patients. The efficacy of chemotherapy drugs in patients with cancer ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68A61K33/243
CPCC12Q1/6886C12Q2600/158C12Q2600/106A61K33/243A61P35/00A61K31/4709G01N33/57423G01N33/57496G01N2333/91215
Inventor 胡安·卡洛斯·拉卡尔圣胡安
Owner TRASLATIONAL CANCER DRUGS PHARMA SL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap